Octreotide in the treatment of refractory diarrhoea and intestinal fistulae
- PMID: 8206397
- PMCID: PMC1374388
- DOI: 10.1136/gut.35.3_suppl.s5
Octreotide in the treatment of refractory diarrhoea and intestinal fistulae
Abstract
Persistent, refractory diarrhoea continues to be an important clinical problem. The mechanisms involved are associated with reduced intestinal absorption and increased intestinal secretion. Reduced intestinal absorption can result from small intestinal resection or from disorders in which there is damage to the small intestine. Motility disorders may also impair absorptive function. The rationale for using octreotide in refractory diarrhoea, intestinal motility disorders, and fistulae relates to its ability to promote intestinal absorption and inhibit gastric, pancreatic, and intestinal secretion. Several clinical studies in patients with short bowel syndrome have reported a reduction of intestinal output in patients taking octreotide compared with controls. Additionally, a number of studies have shown that octreotide improves secretory diarrhoea resulting from neuroendocrine tumours, intestinal infections in AIDS patients, and intestinal graft v host disease. Octreotide may be of use in patients suffering from intestinal motility disorders such as those associated with systemic sclerosis. Octreotide may also be of value in promoting closure of gastrointestinal and pancreatic fistulae.
Similar articles
-
The role of somatostatin analogues in the treatment of refractory diarrhoea.Digestion. 1996;57 Suppl 1:107-13. doi: 10.1159/000201412. Digestion. 1996. PMID: 8813486 Review.
-
Octreotide in the treatment of refractory diarrhea.Digestion. 1999;60 Suppl 2:42-6. doi: 10.1159/000051479. Digestion. 1999. PMID: 10207230 Review.
-
Expanding uses of octreotide.Baillieres Clin Gastroenterol. 1994 Jun;8(2):321-37. doi: 10.1016/0950-3528(94)90007-8. Baillieres Clin Gastroenterol. 1994. PMID: 7949461 Review.
-
Potential indications for octreotide in gastroenterology: summary of workshop.Digestion. 1993;54 Suppl 1:59-67. doi: 10.1159/000201079. Digestion. 1993. PMID: 8359570
-
Effect of octreotide on small intestinal motility in HIV-infected patients with chronic refractory diarrhea.Dig Dis Sci. 2001 Dec;46(12):2636-42. doi: 10.1023/a:1012706908623. Dig Dis Sci. 2001. PMID: 11768253
Cited by
-
Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors.Endocrine. 2003 Apr;20(3):285-90. doi: 10.1385/ENDO:20:3:285. Endocrine. 2003. PMID: 12721509 Review.
-
Functional, Diagnostic and Therapeutic Aspects of Gastrointestinal Hormones.Gastroenterology Res. 2019 Oct;12(5):233-244. doi: 10.14740/gr1219. Epub 2019 Oct 4. Gastroenterology Res. 2019. PMID: 31636773 Free PMC article. Review.
-
Effects of somatostatin on luminal transit and absorption of nutrients in the proximal gut of minipigs.Dig Dis Sci. 1996 May;41(5):894-901. doi: 10.1007/BF02091528. Dig Dis Sci. 1996. PMID: 8625760
-
The Efficacy and Safety of Somatostatin Analog after Axillary Node Dissection in Breast Cancer: A Systematic Review and Meta-analysis.JMA J. 2023 Jul 14;6(3):274-281. doi: 10.31662/jmaj.2022-0219. Epub 2023 May 22. JMA J. 2023. PMID: 37560373 Free PMC article. Review.
-
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.World J Gastroenterol. 2014 Apr 14;20(14):3751-61. doi: 10.3748/wjg.v20.i14.3751. World J Gastroenterol. 2014. PMID: 24744571 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical